The CE-IVD marked automated, next-generation sequencing (NGS) platform allows users to perform diagnostic testing applications and clinical research on a single instrument.
Part of the Ion Torrent Genexus System, the platform is fully validated and provides results in a single day.
Starting from the purified and quantified nucleic acid, the platform automates all the workflow steps of the targeted NGS.
The Genexus Integrated Sequencer also automates the NGS library preparation, sequencing, primary data analysis, template preparation and variant reporting for DNA, RNA, and cfTNA applications.
Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “NGS has become an essential tool to bring the promise of precision medicine therapies to patients.
“With the automated, easy-to-use Genexus Dx Integrated Sequencer, any hospital – including regional and community hospitals – can bring NGS in-house, giving clinicians access to timely, comprehensive genomic profiling results.
“With faster answers, the results can aid clinicians in their patient management decision making, which may include therapeutic options.”
The company is also developing a sample-to-report diagnostic workflow and clinically validated assays portfolio, including comprehensive genomic profiling and hemato-oncology assays.
In 2019, the Ion Torrent Genexus System was introduced as the first fully integrated NGS platform for research use only.
The automated workflow of the platform reduces user intervention, as well as the potential for human error, which makes NGS accessible to all laboratories.
Recently, Thermo Fisher Scientific introduced its Gibco CTS Xenon Electroporation System, which enables large-scale cell therapy development and clinical manufacturing.